Merck & Co. Accused Of Breaking UK Law With Discount Scheme For Biosimilars
Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found that the U.S. company's European unit, Merck Sharp & Dohme, had abused its dominant position through a discount scheme for Remicade.
Remicade, known generically as infliximab, is an antibody drug used to treat conditions such as rheumatoid arthritis and Crohn’s disease.
The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found that the U.S. company's European unit, Merck Sharp & Dohme, had abused its dominant position through a discount scheme for Remicade.
Remicade, known generically as infliximab, is an antibody drug used to treat conditions such as rheumatoid arthritis and Crohn’s disease.